Weaknesses of our study include the use of an orthotopic xenograft rather than a PDX or syngeneic model for FLT3 mutant AML, the small size of our patient cohort for diet testing, the focus on BMAL1, and the off‐target effects of nobiletin and its varied effects across AML cell lines as a single agent. This evidence concerns the gene FLT3 and acute myeloid leukemia.